Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).

Introduction Turoctocog alfa pegol (N8‐GP) is a site‐specific, 40 kDa glycoPEGylated recombinant factor VIII (FVIII) product with an extended half‐life. The comprehensive main phase of the pivotal pathfinder 2 trial showed N8‐GP dosed every 4 days (Q4D) provided favourable safety and efficacy for pr...

Full description

Bibliographic Details
Main Authors: Curry, N, Albayrak, C, Escobar, M, Andre Holme, P, Kearney, S, Klamroth, R, Misgav, M, Négrier, C, Wheeler, A, Santagostino, E, Shima, M, Landorph, A, Tønder, SM, Lentz, SR
Format: Journal article
Language:English
Published: Wiley 2019

Similar Items